menu
    • menu
    [{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Perifosine","moa":"phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"SCRI Development Innovations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Perifosine","moa":"phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeterna Zentaris \/ SCRI Development Innovations, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Aeterna Zentaris \/ SCRI Development Innovations, LLC"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Perifosine","moa":"phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeterna Zentaris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aeterna Zentaris \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Andrew B Lassman","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Perifosine","moa":"phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Pfizer Inc \/ Andrew B Lassman","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Andrew B Lassman"}]

    Find Clinical Drug Pipeline Developments & Deals for Perifosine

    Menu

    Perifosine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pfizer Inc

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Andrew B Lassman

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

                            Details : Perifosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 12, 2014

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Andrew B Lassman

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

                            Details : Perifosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2010

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

                            Details : Perifosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 15, 2010

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of Wisconsin, Madison | Duke University | National Comprehensive Cancer Network (Abbr.) | Pfizer Inc | Aeterna Zentaris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : SCRI Development Innovations, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Perifosine + Capecitabine for Colon Cancer Patients

                            Details : Perifosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colonic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2010

                            Lead Product(s) : Perifosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : SCRI Development Innovations, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth